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Abstract
Abnormalities in mitochondrial function and epigenetic regulation are thought to be instrumental in Huntington’s disease
(HD), a fatal genetic disorder caused by an expanded polyglutamine track in the protein huntingtin. Given the lack of
effective therapies for HD, we sought to assess the neuroprotective properties of the mitochondrial energizing ketone body,
D-b-hydroxybutyrate (DbHB), in the 3-nitropropionic acid (3-NP) toxic and the R6/2 genetic model of HD. In mice treated
with 3-NP, a complex II inhibitor, infusion of DbHB attenuates motor deficits, striatal lesions, and microgliosis in this model
of toxin induced-striatal neurodegeneration. In transgenic R6/2 mice, infusion of DbHB extends life span, attenuates motor
deficits, and prevents striatal histone deacetylation. In PC12 cells with inducible expression of mutant huntingtin protein, we
further demonstrate that DbHB prevents histone deacetylation via a mechanism independent of its mitochondrial effects
and independent of histone deacetylase inhibition. These pre-clinical findings suggest that by simultaneously targeting the
mitochondrial and the epigenetic abnormalities associated with mutant huntingtin, DbHB may be a valuable therapeutic
agent for HD.
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Introduction
Huntington’s disease (HD) is a genetic neurological disorder
caused by the expansion of a trinucleotide CAG repeat that
encodes the polyglutamine region in the huntingtin protein. HD is
characterized by a prominent loss of medium-size spiny neurons
and the formation of protein aggregates in the striatum and the
cerebral cortex [1].
Currently, the pathogenic mechanism leading to neurodegen-
eration in HD has not been fully elucidated. However,
bioenergetic defects and epigenetic modifications have been
proposed to be instrumental [2–4]. Metabolic impairment pre-
cedes the demise of striatal neurons [5,6] and a reduction in
mitochondrial respiration [7] have been detected in HD patients–
consistent with the loss of complex II function induced by mutant
huntingtin (mhtt) [8–10]. Furthermore, inhibition of complex II by
malonate or 3-nitropropionic acid (3-NP) in animal models
reproduces a pattern of striatal lesions similar to that seen in
HD patients [2]. Numerous studies report that mhtt impairs
mitochondrial function [11–13] and dynamics [14–16]. In
addition to mitochondrial abnormalities, mhtt promotes epigenetic
changes by binding to cAMP-responsive element-binding protein
(CREB)-binding protein (CBP). When mhtt binds to CBP, the
histone acetyltransferase activity [17] of CBP is inhibited, leading
to global histone deacetylation [18–20] and consequently, gene
suppression [3]. It is thus conceivable that mhtt can perturb
neuronal function and survival by interfering with the activities of
transcription factors. Consistent with this theory, treatment with
various histone deacetylase (HDAC) inhibitors improves motor
dysfunction, brain pathologies and life expectancy in animal
models of HD [19–23].
D-b-hydroxybutyrate (DbHB) is a ketone body that has been
demonstrated to be neuroprotective [24–28]. We have shown
that in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)
mouse model of Parkinson’s disease, DbHB attenuates loss of
dopaminergic neurons and functional deficits in a dose-dependent
and stereospecific manner [28] by mitigating bioenergetic deficit.
In light of that study, we hypothesized that DbHB may also be
neuroprotective in HD. We report here that DbHB conferred
neuroprotection in both a murine toxic model of striatal neuronal
loss and a genetic model of HD. Importantly, in cell culture and
animal models with mhtt expression, we uncovered a potential
novel protective mechanism of DbHB: preventing the histone
deacetylation induced by mhtt. We believe that both the
bioenergetic and epigenetic actions of DbHB contribute to its
neuroprotective effects in the HD models, and therefore, this
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disorder.
Results
DbHB attenuates striatal lesions induced by 3-NP
We previously demonstrated that DbHB conferred neuropro-
tection through the generation of succinate, a complex II
substrate, in order to bypass complex I inhibition in the MPTP
mouse model of PD [28]. In the present study, we hypothesized
that in the neurotoxic model where 3-NP (a complex II inhibitor)
was used to induce the striatal neuronal loss seen in HD, DbHB
would similarly bypass this inhibition via its generation of the
complex I substrate NADH (Figure 1). To this end, C57Bl/6 mice
were injected with 3-NP in the presence or absence of continuous
DbHB infusion using osmotic minipumps as previously described
[28]. Consistent with its neurotoxic effect, in the group that
received 3-NP alone (Figure 2B), Nissl staining of striatal sections
revealed various sizes of bilateral lesions (marked pallor) in four of
the five surviving animals (five deaths by the end of the 3-NP
treatment, Figure 2J). In contrast, for the group that received
pumps containing DbHB, none of the nine surviving animals (one
death after the 3-NP treatment, Figure 2J) showed a detectable
lesion (Figure 2C). In addition to striatal cell loss, 3-NP has been
reported to induce gliosis [29]. Since DbHB prevented striatal cell
loss, we determined whether this compound also had an effect on
gliosis in these animals by assessing immunoreactivity for
macrophage antigen complex 1 (MAC-1)/CD11b, a marker for
microglia, in striatal sections. As seen in Figure 2E and H,
microglial activity was dramatically upregulated by 3-NP in the
areas corresponding to the lesion core. Discrete, darkly stained
areas (circumscribed) were readily visualized from these sections.
Figure 1. Metabolic pathways of DbHB in mitochondria. The
metabolism of DbHB in mitochondria is stereospecific to the D isoform.
Under normal physiological conditions, the level of DbHB is low but
becomes dramatically elevated during starvation, increased fatty acid
metabolism or pathological conditions such as diabetes. From its site of
production in the liver, DbHB is released into the blood and circulated
for utilization by other tissues. In general, the rate of ketone body usage
in the brain is proportional to the concentration in the circulation [59].
Circulating DbHB readily crosses the blood-brain barrier and enters
brain mitochondria where it is metabolized by mitochondrial b-
hydroxybutyrate dehydrogenase to acetoacetate, which is subsequent-
ly converted to acetyl-coenzyme A to feed into the tricarboxylic acid
cycle (TCA) cycle. The intermediate products generated from this cycle,
NADH and succinate, in turn feed into the electron transport chain to
subsequently generate ATP at complex V. Through this metabolic
pathway, DbHB is an excellent alternative source of energy in the brain
when glycolysis is not operative or when glucose supply is depleted
such as during starvation [59].
doi:10.1371/journal.pone.0024620.g001
Figure 2. DbHB attenuates striatal lesions induced by 3-NP.
Male C57Bl/6 mice (,21 weeks-old) was infused subcutaneously (1 ml/
h) with either DbHB (1.6 mmol/kg in saline) or vehicle (saline) using
implanted osmotic minipumps. One day after surgery, each animal
group was further subdivided into two groups to receive nine i.p.
injections of either saline or 3-NP (50 mg/kg) at 12 h intervals. Five
hours after the last 3-NP injection, animals were intracardially perfused
with 4% paraformaldehyde. As compared to control (A), 3-NP induced
significant cell loss (pale region) as seen here with Nissl stain (B). This
lesion was not detectable in the group that received DbHB infusion (C).
DbHB by itself did not affect the baseline level (not shown) of Nissl
staining. Immunoreactivity for MAC-1/CD11b was observed after 3-NP
treatment (E, H) in the lesioned area (outlined) as compared to the
saline control group (D, G). Although 3-NP also induced discrete
regions of increased microglia reaction in some animals that received
DbHB (F, I), the immunoreactivity was not as dramatic as compared to
the 3-NP treated group (E, H). Panel J summarizes the death rate and
numbers of animals with striatal lesions induced by 3-NP in the groups
that received either saline or DbHB infusion. Panel K demonstrates
comparable magnitude of complex II inhibition in the two 3-NP treated
groups, indicating that DbHB did not interfere with the function of
complex II per se.
doi:10.1371/journal.pone.0024620.g002
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showed strong microglial activation. Although microglial activa-
tion was observed in five out of nine surviving animals in the group
that received DbHB (Figure 2F and I), microgliosis did not appear
to be as robust as the saline group (Figure 2E and H).
To exclude the possibility that DbHB conferred protection by
interfering with the levels of 3-NP in the brain, we performed
histochemical analyses to compare succinate dehydrogenase (com-
plex II) activity in striatal sections in animals treated with and
without DbHB. Complex II inhibition induced by 3-NP was of
comparable magnitude between these groups, demonstrating DbHB
did not reduce the pharmacological effect of 3-NP (Figure 2K).
Together, these results suggest that in this metabolic defect model of
striatal neuronal damage, DbHB attenuates neurodegeneration
probably through its well established bioenergic effect.
DbHB attenuates motor deficits induced by 3-NP
In addition to the large striatal lesions observed, this 3-NP
regimen induces severe locomotor abnormalities by the end of the
treatment [29]. To quantify the magnitude of this behavioral
abnormality in the presence of DbHB, C57Bl/6 mice were treated
with 3-NP and DbHB as described in Figure 2 and five hours after
the last 3-NP injection (the same time point used in Figure 2),
locomotor activity was assessed using infrared photobeam
chambers. As seen in Figure 3, animals treated with 3-NP alone
were almost completely immobilized; however, DbHB partially
improved motor dysfunction induced by 3-NP.
DbHB delays motor deficits in R6/2 mice
Because HD is a genetic disorder, to assess the potential clinical
relevance of DbHB for HD, we infused this compound in
transgenic R6/2 mice, an HD model in which both mitochondrial
dysfunction and epigenetic modifications have been demonstrated.
Additionally, a clear and rapid progression of the disease
(phenotype, neuropathology and life-span) in these mice make
them an ideal model for us to test the protective effects of DbHB.
Six week old male transgenic-R6/2 mice and their non-transgenic
littermates were subcutaneously implanted with osmotic mini-
pumps containing DbHB or saline for the entire period of study.
Pumps were replaced every two weeks. Beginning one week after
implantation, mice were assessed for locomotor activity using
open field automated chambers. As seen in Figure 4, although
moderate, DbHB significantly attenuated the severity of motor
deficits in these animals. DbHB did not have an effect in non-
transgenic wild type littermates (not shown).
DbHB significantly extends life-span in R6/2 mice
Life expectancy of the animals described in Figure 4 was
monitored. In the group that received vehicle control, most
transgenic animals died by 90 days. However, DbHB significantly
extended the survival time (Figure 5A). The mean survival time in
the DbHB treated group increased by ,30.0% over the saline
treated group (DbHB group=108.764.3, saline group=83.662.3,
expressed as days 6 SEM, p,0.001). None of the non-transgenic
animals died by the end of this experiment. Perhaps due to the
presence of polyQ aggregates in the pancreas leading to reduced
mass and function of b-cell as well as interference with
transcriptional regulation in islets, some of these transgenic mice
have also been reported to develop diabetes towards the end stage of
life expectancy [30–32]. To determine if this cohort of R6/2 mice
also had this complication and whether DbHB was protective
against this metabolic defect, blood glucose levels were monitored.
We observed that up to the time point that most of these mutant
mice died (13
th week), glucose levels remained normal, although for
one mouse that survived up to 14 weeks, we did detect an elevated
glucose level. Thus diabetes alone could not account for the
increased death rate in these mice. In mutant mice treated with
DbHB, glucose levels remained low for all animals (Figure 5B).
However, it is unlikely that DbHB extended life expectancy in these
transgenic mice through the improvement of diabetes because as
discussed above, high blood glucose is not a prominent feature in
this cohort. Regardless, because this metabolic disorder also occurs
in HD patients [33], this stabilizing effectof DbHB on glucose levels
may be a desirable feature for HD.
Figure 3. DbHB attenuates motor deficits induced by 3-NP. Male C57Bl/6 mice (,21 weeks-old) were treated with 3-NP and DbHB as
described in Figure 1. Five hours after the last 3-NP injection, mice were assessed for locomotor activities using infrared photobeam chambers. In the
group that received saline infusion (n=12), 3-NP injection induced dramatically impaired locomotor movements. In contrast, these abnormalities
were attenuated in the 3-NP group that received DbHB infusion (n=7). Units expressed as % of the saline injected control group (not shown) 6 SEM.
*p,0.05 as compared to the 3-NP treated mice that receive saline infusion.
doi:10.1371/journal.pone.0024620.g003
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R6/2 mice
Neuropathology and gross morphological changes were also
assessed in animals recovered from the experiments described in
Figure 5. Three features commonly found in transgenic-R6/2
mice are striatal atrophy, protein aggregation and histone
deacetylation. Although we observed a reduction in striatal
volume in transgenic animals, we did not detect an overall change
in striatal volume in these mutant animals treated with or without
DbHB (data not shown). Nor did we detect an apparent difference
in protein aggregation in striatal sections immunostained with an
antibody (EM48, Chemicon International Inc.) against huntingtin
(data not shown). However, DbHB dramatically restored the
epigenetic abnormality in these animals. As illustrated in Fig. 6,
consistent with other studies [20,34], we confirmed histone
deacetylation in transgenic mice by incubating striatal tissue
sections with polyclonal antibodies against acetyl-histone H4.
DbHB treatment blocked histone deacetylation in the transgenic
Figure 4. DbHB attenuates motor deficits in Transgenic-R6/2 mice. Six week old male transgenic (Tg)-R6/2 mice and non-transgenic (Ntg)
littermates were infused with either saline vehicle or DbHB as described in Figure 2. Osmotic minipumps were replaced every two weeks for the
entire study period. Locomotor activities were assessed using infrared photobeams chambers. Tg-R6/2 mice displayed significant impairment in
locomotor movements. In contrast, these abnormalities were delayed and less severe in the Tg group treated with DbHB (n=7). DbHB did not affect
locomotor function of Ntg mice (not shown). Units expressed as % control of Ntg-Saline group at seven weeks old (n=12). *p,0.05 as compared to
the respective Tg-saline groups (n=7) at the same time points.
doi:10.1371/journal.pone.0024620.g004
Figure 5. DbHB extends life expectancy and stabilizes glucose levels of Tg-R6/2 mice. Animals from Figure 4 were monitored twice daily
for their survival rate (A). These mice were considered to reach their end stage if they were unable to right themselves after being placed on their
back or died overnight. DbHB significantly extended the survival time in Tg-R6/2 mice. n=12 (Ntg-saline), n=7 (Tg-saline), n=7 (Tg-DbHB). p,0.001
Kaplan-Meier analysis between Tg-sal and Tg- DbHB groups. These animals were also assessed weekly for glucose levels after six hours of fasting (B).
One animal from the Tg-saline group survived up to 14 weeks and exhibited an elevated glucose level.
doi:10.1371/journal.pone.0024620.g005
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bioenergetic effects, DbHB may also confer protection to the R6/
2 mice through restoring epigenetic alterations induced by mhtt.
DbHB prevents histone deacetylation induced by mhtt
Primarily based on its similar chemical structure to the histone
deacetylase (HDAC) inhibitor sodium butyrate, we hypothesized
that DbHB would also attenuate histone deacetylation induced by
mhtt via HDAC inhibition. To assess this possibility, we used stably
transfected PC12 cells with inducible expression of human mutant
(Htt
Q103) and normal (Htt
Q25) huntingtin. Htt
Q103 cells have been
reported to display histone deacetylation [18]. These stable cells
were treated with or without 1 mM tebufenozide for the induction
of huntingtin expression, in the presence or absence of DbHB,
LbHB (a mitochondrially inactive isomer of DbHB) or sodium
butyrate as the positive control. As illustrated in Figure 7, 48 h
after induction, mhtt dramatically reduced the extent of
acetylation on histone H4 (100%63.12 vs 39.37%66.71, Panels
A and B) in the Htt
Q103 cells. This reduction was absent in the
Htt
Q25 cells (Panel C), suggesting a specific effect of mhtt. The
dose-response study shows DbHB and sodium butyrate signifi-
cantly increased histone H4 acetylation at a concentration of
4m M(P a n e lA )i nHt t
Q103cells. LbHBalsohadsimilardose-response
effect to DbHB (data not shown). Quantitatively, at an equimolar
concentration (4 mM, Panel B), both DbHB and LbHB completely
preserved the levels of histone acetylation (89.46%611.66 and
105.25%624.65, respectively). In contrast, sodium butyrate dramat-
ically increased the acetylation level to 952.65%624.65 – suggesting
a different mechanism exists in these two classes of compounds. This
pattern of dramatic difference was also detected in the Htt
Q25 cells
(Panel C)w h e r eD bHB and LbHB did not change the baseline of
histone acetylation but a significant increase was induced by sodium
butyrate.
DbHB prevents histone deacetylation via an HDAC
independent mechanism
To further assess whether the effects of DbHB and LbHB on
blocking histone deacetylation was a result of HDAC inhibition,
we measured HDAC activities in the presence or absence of these
compounds. Sodium butyrate served as a control. First, we
measured the inhibitory effect of these compounds against classes I
and II HDAC. Trichostatin A (1 mM) was used as an additional
positive control for class I and II HDAC inhibition. As expected,
both trichostatin A and sodium butyrate inhibited the activity of
these enzymes (Figure 8A). However, DbHB and LbHB did not
have this inhibitory effect. Even at a concentration up to 10 mM,
these two compounds did not inhibit HDAC activity (data not
shown). Since these compounds may potentially inhibit a third
class of HDAC, we also assessed the effects of DbHB and LbHB
on the enzymatic activity of HDAC class III. We also did not
detect inhibitory effects of DbHB and LbHB against this enzyme
(Figure 8B). Consistent with its role as an inhibitor of HDAC I and
II, sodium butyrate also did not have an effect here. As a positive
control, nicotinamide, an HDAC III inhibitor, almost completely
inhibited this activity. Together, these results indicate that both
mitochondrially active and inactive forms of beta-hydroxybutyrate
prevent histone deactylation induced by mhtt via an HDAC-
independent mechanism.
Discussion
The neuroprotective effects of DbHB have been demonstrated
in various models of neurological disorders [24–28]. We previously
showed that in the MPTP mouse model of Parkinson’s disease,
DbHB attenuated loss of dopaminergic neurons and functional
deficits in a dose-dependent and stereospecific manner via its
bioenergetic effect [28]. In the present study, we report that DbHB
is neuroprotective in both mitochondrial toxin induced striatal
neurodegeneration and a genetic mouse model of HD. It is likely
that the bioenergetic effects of DbHB contributed to the protection
in these models. Although the epigenetic effects observed in the
present genetic model may also play a role, it requires further
studies.
In addition to its adverse effects on mitochondria, mhtt induces
transcriptional dysregulation by binding to the cAMP-responsive
element-binding protein (CREB)-binding protein (CBP), which
also functions as a histone acetyltransferase (HAT) [17]. The
expanded glutamine stretch in mhtt has been shown to bind to
either the polyQ domain of CBP and sequester it in nuclear
inclusions [35–37] or bind to the acetyltransferase domain (outside
the polyQ domain) in CBP [18,38], leading to the inhibiton of the
HAT activity of CBP and ultimately, global histone deacetylation
[18–20]. This reduction in histone acetylation, in turn, leads to
gene silencing [3]. By increasing histone acetylation, histone
deacetylase (HDAC) inhibitors improve motor dysfunction and
brain pathologies, as well as increases life expectancy in animal
models of HD [19–21]. Based on its similar chemical structure to
Figure 6. DbHB prevents histone deacetylation induced by
mhtt. Animals recovered from the survival study were perfused and
striatal sections were obtained and immunostained for histone H4
acetylation. Immunoreactivity was visualized by incubation in 3,39-
diaminobenzidine . There was less immunoreactivity of histone H4
acetylation in the transgenic animals as compared to the Ntg mice.
DbHB treatment restored H4 acetylation in the Tg animals. n=2
representative animals per group.
doi:10.1371/journal.pone.0024620.g006
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initially hypothesized that DbHB would attenuate abnormal levels
of histone deacetylation induced by mhtt via HDAC inhibition.
Our subsequent studies demonstrated that although DbHB did
prevent histone deacetylation induced by mhtt, the mechanism
was not mediated by HDAC inhibition. Because DbHB is a well-
established mitochondrial substrate, we assessed whether the
observed epigenetic effect was mediated through mitochondria.
The metabolism of DbHB to acetoacetate in mitochondria by b-
hydroxybutyrate dehydrogenase is stereospecific [39]. Although
cytosolic enzymes have been reported to metabolize LbHB in
chicken liver [40] and sheep kidney [41,42], there is no evidence to
support the existence of either a mitochondrial L-3-hydroxybuty-
rate dehydrogenase or a racemase that interconverts the L- and D-
isoforms of b-hydroxybutyrate [39]. Consistent with this, in our
previous study using polarography we confirmed that DbHB, but
not LbHB, could support mitochondrial respiration leading to
higher ATP production [28]. Therefore, our data suggest that
DbHB did not restore histone acetylation via a mitochondrial
mechanism, because its mitochondrially inactive isomer, LbHB,
produced the same epigenetic changes.
The precise mechanism by which DbHB prevents histone
deacetylation induced by mhtt requires additional investigations.
In general, there are a few potential mechanisms by which DbHB
Figure 7. DbHB and LbHB prevent histone deacetylation induced by mhtt. (Panel A): Dose-response study of DbHB and sodium butyrate
(0.25 mM-4 mM) in PC12 cells with inducible expression of Htt
Q103 upon addition of tebufenozide (1 mM) using immunoblotting. Two microgram of
histones extracted from Hela cells treated with 5 mM sodium butyrate (obtained from Upstate Biotechnology Inc.) was used as a positive control
(‘‘+C’’). Levels of histone acetylation were quantified in cells with mutant (Panel B, Htt
Q103) or normal (Panel C, Htt
Q25) huntingtin 48 h after
induction in the absence (‘‘0’’) or presence of equimolar concentrations (4 mM) of DbHB (‘‘D’’), LbHB (‘‘L’’) or sodium butyrate (‘‘Na’’) and compared
with the non-tebufenozide treated control group (‘‘C’’). Data represent n=6–10 per group (pooled from three separate experiments). *p,0.01 as
compared to the control group (‘‘C’’) without tebufenozide treatment.
doi:10.1371/journal.pone.0024620.g007
Figure 8. DbHB and LbHB do not inhibit HDAC activities. Hela nuclear extract was used as a source of class I and II HDAC activity (Panel A)
where as recombinant human Sir1 was used as a source of class III HDAC activity (Panel B). HDAC activities were assessed in the absence (control,
‘‘C’’) or presence of 4 mM DbHB (‘‘D’’), LbHB (‘‘L’’) or sodium butyrate (‘‘Na’’, an HDAC I and II inhibitor), 1 mM trichostatin A (‘‘TA’’, an HDAC I and II
inhibitor) or 1 mM nicotinamide (‘‘Nic’’, an HDAC III inhibitor). Activities were quantified based on fluorescence intensity and expressed as arbitrary
fluorescence unit (AFU). n=6–16 per group from 5 independent experiments.
doi:10.1371/journal.pone.0024620.g008
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HDAC activity, 2) Increase general histone acetyltransferase
activity, 3) Reduce mhtt-induced protein aggregation, leading to
less sequestration of CBP, and 4) Block the binding of mhtt to the
active site of CBP, maintaining the normal HAT activity of this
protein. We have eliminated the first possibility by demonstrating
that DbHB did not inhibit any of the three classes of HDAC.
Regarding the second possibility, we reasoned that if DbHB
increased a general HAT activity, we would have detected an
increase in histone acetylation when Htt
Q25 cells were treated with
this compound. This rationale is further supported by the fact that
when these cells were treated with a general HDAC inhibitor
(sodium butyrate), histone acetylation was increased. A general
mechanism such as inhibiting HDAC or stimulating HAT should
lead to an increase in histone acetylation, regardless of the
presence of mhtt or normal htt. The fact that we only observed a
DbHB-mediated increase in histone acetylation in cells with mhtt
and that this increase was only to restore acetylation to the
baseline level rather than the dramatic increase seen with sodium
butyrate, led us to the remaining two possibilities. However, based
on our immunohistochemical observations in both stable PC12
cells and R6/2 mice, DbHB does not appear to reduce protein
aggregation (data not shown). Therefore, we are left with our last
hypothesis. That is, this effect of DbHB is specific to mhtt and it
may be mediated through blocking the binding of mhtt to CBP,
leaving the HAT activity of this protein intact. It is worth noting
that in addition to CBP, other proteins with HAT activity such as
p300 and P/CAF may also interact with mhtt [18]. Thus, the
effect of DbHB may not be restricted to just CBP.
Although DbHB extended the life span of R6/2 mice quite
dramatically, DbHB did not produce a similarly striking
improvement in motor deficits in these animals. This lack of
robust effect may be a result of the experimental regimen. Because
the half-life of DbHB is only about 1.64 h [43], it had to be
delivered through osmotic minipumps. The large size of these
pumps necessitated waiting until mice were six weeks old to
implant them and begin treatment. However, R6/2 mice start to
exhibit motor deficits as early as three-four weeks old and by six
weeks already exhibit marked locomotor deficits [44,45]. Thus,
beginning DbHB infusion at six weeks was likely too late to get the
maximum benefits of this molecule. Consistent with this theory,
when these mice were treated beginning at seven weeks old, we did
not detect such a clear trend of improvement in motor deficits
(data not shown). As discussed in other reviews [46,47], an early
HD neurological phenotype, probably as a result of neuronal
dysfunction, occurs before the overt appearance of protein
aggregations or neurodegeneration. This neuronal dysfunction is
likely mediated by interactions between mhtt and other proteins
[47]. Relevant to our working hypothesis is the binding of mhtt to
CBP, leading to histone hypoacetylation. The effects of gene
silencing as a consequence of histone deacetylation very likely play
a major role in early neurological deficits in HD patients and R6/
2 mice. The ability of DbHB to prevent histone deacetylation
induced by mhtt leads us to hypothesize that if given early enough
and at a sufficient concentration to prevent the interactions
between mhtt and CBP, DbHB may further attenuate neurolog-
ical deficits in these animals. Future studies using mouse models
with slower onset of symptoms or developing a means of delivering
DbHB in mice younger than six weeks old are necessary to address
this issue.
The short half-life of DbHB raises the question of whether this
compound would be a feasible treatment for human diseases. We
believe the first crucial step in drug discovery is to identify an
active compound. Once such a compound has been identified,
current pharmaceutical technology is readily available to improve
such unfavorable pharmacokinetic profiles as a short half-life. For
example, the compound of interest can be encapsulated in a
polymer matrix facilitating slow release over time. This strategy is
widely utilized by pharmaceutical companies and has been applied
to control the release of levodopa (SinemetH CR) for the treatment
of Parkinson’s disease. Relevant to the present study, orally active
forms of DbHB with more favorable pharmacoketics are currently
being developed by KetoCytonyx Inc, a biotechnology company
dedicated to the use of ketone bodies for the treatment of various
human diseases [27]. Similar, Accera Inc. has recently marketed
Axona
TM, a medium chain triglyceride to generate ketone bodies,
for the treatment of Alzheimer’s disease. In addition to the
pharmaceutical form of DbHB, non-pharmacological approaches
such as a ketogenic diet (KD) and caloric restriction can also
produce higher levels of this molecule in the body. Although not
palatable and hyperlipidimic, KD has been used successfully for
almost a century for the treatment of refractory epilepsy in
children. KD has also been demonstrated to be beneficial in
transgenic mouse models of Alzheimer’s disease [48] and
Amyotrophic Lateral Sclerosis [49] as well as in patients with
Parkinson’s disease [50] and Alzheimer’s disease [51]. Caloric
restriction (e.g., alternate day fasting) leading to higher serum
DbHB concentrations is also neuroprotective [52–55].
In summary, the present study adds HD to a growing list of
neurological disorders in which DbHB may confer neuroprotec-
tion. In addition to its well established mitochondrial effect, we
may also unravel a novel epigenetic function of this molecule,
leading to new insights into the mechanism by which it confers
neuroprotection in treating epilepsy and other neurological
disorders. Numerous studies have demonstrated the beneficial
effects of increasing histone acetylation in HD [19–23]. Although
we were unable to precisely elucidate the epigenetic mechanism of
DbHB or to fully establish a direct link between its restoration of
histone acetylation and neuroprotection, we believe the overall
positive results in the present study serve as a starting point that
encourages further investigations into the potential clinical
relevance of this compound for HD.
Materials and Methods
Ethics Statement
All experiments were approved by the Institution Animal Care
and Use Committee of the University of Rochester under the
protocol number 2007-063.
Animals and treatment
3-NP model: DbHB (1.6 mmol/kg/d in saline) or vehicle (saline)
was infused (1 ml/h) in male C57Bl/6 mice (,21 weeks-old) using
subcutaneously implanted AlzetH osmotic minipumps (Model
2001, DURECT Corp., Cupertino, California, USA). This dosage
of DbHB was chosen based on our previous dose-response study
[28] showing that this concentration yielded approximately
threefold increase in baseline plasma levels of DbHB (,1.0 mM)
and conferred maximal neuroprotection against MPTP toxicity.
One day after implantation, each animal group was further
subdivided into two groups to receive nine i.p. injections of either
saline or 3-NP (50 mg/kg in 0.1 M PBS, pH 7.4) at 12 h intervals
as described by Beal and colleagues [29]. Five hours following the
last 3-NP injection, animals were anesthetized with pentobarbital
(35 mg/kg, i.p.) and intracardially perfused with cold 4% (w/v)
paraformaldehyde in 0.1 M PBS (pH 7.4). Their brains were
removed, postfixed in the same fixative overnight at 4uC,
cryoprotected in 30% (w/v) sucrose for 48 h at 4uC and then
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(30 mm) spanning the entire striatum were collected free-floating
in phosphate buffer prior to immunohistochemical analyses. R6/2
model: Female hemizygous R6/2 breeders (with ovarian transplant)
were purchased from the Jackson Laboratories and bred with male
B6CBAFI/J mice to maintain the same background. The offspring
were genotyped using tail DNA. As with the 3-NP study, animals
were subcutaneously infused with either saline vehicle or DbHB
(1.6 mmol/kg/d) using AlzetH osmotic minipumps (Model 2002).
Six week old animals were used because younger mice were too
small to accommodate these osmotic pumps, which were replaced
every two weeks throughout the study period. Only male mice
were used.
Locomotor activity testing
Automated chambers (Env-510, Med Associates, St. Albans,
Vermont) were used to quantify locomotor activity. Each cham-
ber (10.750L610.750W680H), with sound isolation cubicles, is
equipped with infrared photobeams (3 mm in diameter) separated
by 24.4 mm on a horizontal plane, 39 mm from the floor of the
chamber. A second set of photobeams located 57 mm above the
horizontal photobeams divides the chamber vertically. Using
the Open Field Activity SoftwareH provided by the company,
photobeam breaks were recorded every 5 minutes for 30 minutes
to quantify vertical, traveled distance, jumps and ambulatory
movements. For the 3-NP treated mice, animals were assessed five
hours following the last 3-NP injection. R6/2 mice were assessed
weekly, starting one week after the implantation of the pumps.
Survival analysis
For the survival studies of R6/2 mice, we adopted the criteria
described previously [20] to determine the end point of an animal.
Animals were observed twice daily, morning and late afternoon.
When the animals were inactive and unable to right themselves
after being placed on their back, they were euthanized with a
lethal dose of pentobarbital. Animals that died overnight were
recorded the next morning. This study was done in the same
groups of mice used for behavioral assessment.
Assessment of striatal lesions in the 3-NP model
Striatal sections obtained from 3-NP injected mice were stained
with thionin (Sigma-Aldrich) for Nissl substance to assess for the
striatal lesions or immunostained for MAC-1/CD11b (Serotec) for
microgliosis. Biotinylated secondary antibodies followed by avidin-
biotin complex were used. Immunoreactivity was visualized using
3,39-diaminobenzidine (DAB)/glucose oxidase/glucose.
Blood glucose measurement
Glucose levels were measured in a drop of blood obtained from
the mouse tails using a glucometer (AccuCheck AdvantageH,
Roche Diagnostics). After each session of locomotor activity
testing, blood glucose levels were measured following six hours of
fasting.
Complex II histochemistry
As described previously [28,56], animals were perfused with
PBS containing 10% glycerol. Brains were rapidly removed and
frozen in dry-ice cooled isopentane and stored at 280uC. Brains
were sectioned at 20 mm throughout the entire striatum and
mounted onto glass microscope slides at every 8
th section intervals.
Complex II activity was revealed by incubating sections at 37uC
for 20 min in 50 mM phosphate buffer (pH 7.6) containing
50 mM succinate as a substrate and 0.3 mM nitro blue
tetrazolium (NBT) as an electron acceptor. Striatal optical density
of NBT was digitalized and quantified by using Scion Image
program (Scion Corp., Frederick, Maryland, USA).
Cell cultures and treatment
The genetically engineered pheochromocytoma cells (PC12)
were provided by Dr. Erik Schweitzer. The process of generating
these cells is well described [57]. Briefly, these cells are stably
transfected with a DNA insert encoding exon 1 of human
huntingtin expressing 103 CAG (polyQ) repeats (Htt
Q103) fused to
EGFP. Control cells express the normal length of polyQ (Htt
Q25).
The expression of these proteins is inducible by ecdysone or its
analog tebufenozide, which was provided by Dr. Fred Gage (Salk
Institute, CA). These cells display abundant protein aggregates
and cell death occurs by 48 h after induction of mhtt [57]. Cells
were grown in T75 flasks in DMEM medium supplemented with
10% horse serum, 5% fetal bovine serum and 0.5 mg/ml G418.
Two days later, spent medium was replaced with fresh medium
with or without 1 mM tebufenozide for the induction of huntingtin
expression, in the presence or absence of DbHB, LbHB or sodium
butyrate. After 48 h of induction, cells were trypsinized and
collected for histone extraction.
Histone Extraction and Immunoblotting
Histones of cultured cells were extracted as described previously
[58]. Cell pellets collected from T75 flasks as described above were
Dounce homogenized in ice-cold lysis buffer (10 mM Tris-HCl,
50 mM sodium bisulfite, 1% Triton X-100, 10 mM MgCl2, 8.6%
sucrose, pH 6.5). The nuclei were collected by centrifugation at
1,0006g for 10 min, washed three times with lysis buffer followed
by one wash of 10 mM Tris-HCl, 13 mM EDTA. pH 7.4. The
pellet was suspended in 0.1 ml of ice-cold H2O and concentrated
H2S04 was added to the suspension to give a final concentration of
0.4 N. After incubation at 4uC for at least 1 h, the suspension was
centrifuged at 15,0006g for 5 min using a microcentrifuge. The
supernatant was transferred and mixed with 1 ml of acetone. After
overnight incubation at 220uC, the coagulated material was
collected by microcentrifugation at 15,0006g for 5 min and air-
dried. This acid soluble histone fraction was dissolved in H2O.
Protein concentrations were determined using BCA assay (Pierce,
Rockford, IL). Proteins (20 mg/lane) were separated by gradient
5–15% Tris/Tricine-PAGE, transferred to PVDF membranes and
blotted with antibodies against acetyl-histone H4 (1:2,000).
Antibody against histone H2A was used for loading controls to
indicate equivalent amounts of histones were loaded. All of the
histone antibodies were purchased from Upstate Biotechnology
Inc. (Lake Placid, NY). These primary antibodies were incubated
overnight at 4uC. Secondary antibodies conjugated with horse-
radish peroxidase were used and visualized by chemiluminescence
(SuperSignal Ultra, Pierce, Rockford, IL). Bands of interest were
analyzed and quantified using Scion Image.
HDAC Activities
Activities of HDAC classes I, II and III were measured using the
fluorometric HDAC Assay Kits (Upstate Biotechnology Inc.)
according to the instructions provided by the company. Briefly,
Hela nuclear extract was used as a source of classes I and II
HDAC activity. Recombinant human Sir1 served as a source of
class III HDAC. Equimolar concentrations (4 mM) of our
compounds of interest—DbHB, LbHB and sodium butyrate—
were incubated with this extract and the signals were measured
using a fluorescence 96-well plate reader (excitation=365 nm,
Emission=450 nm). Trichostatin A (1 mM) was used as a positive
control for class I and II HDAC inhibition whereas nicotinamide
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expressed as arbitrary fluorescent units (AFU) and were within
the linear range of the standard curve.
Statistics
All values were expressed as mean 6 standard error of the mean
(SEM). Differences between means were analyzed using either t-
test, one-way or two-way analysis of variance (ANOVA), with the
different types of mice, treatment or time as the independent
factors. When ANOVA shows significant differences, Newman-
Keuls post-hoc testing was used to test pair-wise comparisons
between means. The null hypothesis was rejected at the level of
0.05. Survival data was analyzed using Kaplan-Meier analysis. All
statistical analyses were performed using SigmaStat-3.0 (Jandel
Corporation, San Rafael, CA).
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